These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35227644)

  • 1. Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2.
    Sun X; Dong M; Gao Y; Wang Y; Du L; Liu Y; Wang Q; Ji K; He N; Wang J; Zhang M; Gu Y; Song H; Zhai H; Feng L; Xu C; Liu Q
    Biochem Pharmacol; 2022 May; 199():114981. PubMed ID: 35227644
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
    Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
    Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
    Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
    Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
    Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
    Wang Q; Ma J; Lu Y; Zhang S; Huang J; Chen J; Bei JX; Yang K; Wu G; Huang K; Chen J; Xu S
    Oncogene; 2017 Sep; 36(37):5321-5330. PubMed ID: 28534518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis.
    Zhang L; Xu Y; Cheng Z; Zhao J; Wang M; Sun Y; Mi Z; Yuan Z; Wu Z
    Cancer Lett; 2024 Jul; 595():217000. PubMed ID: 38821254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
    Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
    Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPIA dictates NRF2 stability to promote lung cancer progression.
    Lu W; Cui J; Wang W; Hu Q; Xue Y; Liu X; Gong T; Lu Y; Ma H; Yang X; Feng B; Wang Q; Zhang N; Xu Y; Liu M; Nussinov R; Cheng F; Ji H; Huang J
    Nat Commun; 2024 Jun; 15(1):4703. PubMed ID: 38830868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.
    Riaz MA; Sak A; Erol YB; Groneberg M; Thomale J; Stuschke M
    Sci Rep; 2019 Feb; 9(1):1282. PubMed ID: 30718758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway.
    Yu C; Jiao Y; Xue J; Zhang Q; Yang H; Xing L; Chen G; Wu J; Zhang S; Zhu W; Cao J
    Int J Biol Sci; 2017; 13(12):1560-1569. PubMed ID: 29230104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer.
    Meng Y; Lin W; Wang N; Wei X; Huang Q; Liao Y
    Free Radic Biol Med; 2023 Feb; 196():65-80. PubMed ID: 36646328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
    Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
    Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
    Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
    [No Abstract]   [Full Text] [Related]  

  • 18. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
    Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
    Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
    Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
    ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.